摘要
Notch信号通路进化保守,分为经典通路和非经典通路。生理上,Notch受体经3次切割后释放胞内结构域NICD至细胞核中,调节靶基因的转录,对动物发育、组织更新修复等生物过程进行调控;病理上,Notch的遗传突变或信号异常可促进或抑制多种疾病的进展,在癌症和非癌性疾病中存在着复杂机制。虽然在研药物较多,涉及Notch信号通路的各个环节,但仍未有明确有效的上市药物。因此对Notch途径进行更深入的研究,依照疾病类型及Notch信号通路不同环节进行整体评估和探讨,进而发现更有希望的靶向Notch的治疗方法是非常必要的。
Notch signaling pathway evolved conservatively.The Notch signaling pathways include'canonical'and'non-canonical'pathways.Physiologically,the intracellular domain NICD is released into the nucleus after Notch receptor is cleaved three times,and then regulates biological processes such as animal development,tissue renewal and repairment by regulating the transcription of target genes in nucleus.Notch genetic mutations or signaling abnormalities can promote or inhibit the progression of various diseases and the mechanism is complex in cancer and non-cancer diseases.A series of drugs candidates involved in the Notch signaling pathway have been evaluated although there are no drugs on the market yet.Therefore,it is necessary to study the Notch pathway thoroughly.
作者
王子含
阿基业
王广基
谢媛
WANG Zihan;A Jiye;WANG Guangji;XIE Yuan(Key Laboratory of Drug Metabolism and Pharmacokinetics,China Pharmaceutical University,Nanjing 210009,China)
出处
《药物评价研究》
CAS
2023年第9期2006-2013,共8页
Drug Evaluation Research
